Le Lézard
Classified in: Health, Covid-19 virus
Subjects: TRI, FDA

DiaCarta Inc. has filed for EUA with the FDA and has received CE mark for its highly sensitive QuantiVirustm SARS-CoV-2 Test


RICHMOND, Calif., March 24, 2020 /PRNewswire/ -- DiaCarta Inc., a precision molecular diagnostic company, announced today that it has filed for Emergency Use Authorization (EUA) with the US FDA for its QuantiVirustm SARS-CoV-2 test and has validated the COVID-19 diagnostic test in its own CLIA certified lab in Richmond, CA to provide testing services for healthcare providers and patients. DiaCarta recently received Conformitè Europëenne (CE) Mark for its product.

The in vitro diagnostic test based on Real-Time PCR technology is developed for specific detection of SARS-CoV-2 viral RNA extracted from nasopharyngeal swabs, oropharyngeal swabs and sputum from patients suspected with coronavirus infection. Three genes of SARS-CoV-2 including N, Orf1ab and E genes are targeted in the real-time PCR (qRT-PCR) assay to ensure high degree of sensitivity and accuracy. The analytical sensitivity is 1-5 copy/uL of SARS-CoV-2 viral RNA for patient sample with a 95% confidence. Clinical validation of the assay showed 96.7% sensitivity and a specificity of 100%, with no cross-reaction to different types of non-SARS-CoV-2 species.

"We are pleased that we can offer our QuantiVirustm SARS-CoV-2 product to healthcare providers and as a CLIA validated test to our customers," said Dr. Ram Vairavan, Senior Vice President of DiaCarta Inc., "as it will help to fulfil an urgent need, as the coronavirus pandemic continues to shut down daily life across the globe."

About DiaCarta Inc.,

DiaCarta is a molecular diagnostics company that has developed innovative technologies that transforms patient care by providing effective precision diagnostics using liquid biopsy.  Its novel XNA technology provides high level of sensitivity as it binds to the wild-type sequence and enables only the mutant target sequence to get amplified. Using this technology, the company has developed its highly sensitive ColoScapetm Colorectal Cancer Mutation test. Powered by its SuperbDNAtm technology that provides high level of detection as it amplifies the signal and requires no RNA/DNA extraction or amplification, the company has developed its revolutionary RadToxtm test that personalizes radiation therapy, mitigates adverse events and enhances patient care. Based in Richmond, California the company is GMP-compliant and offers CLIA certified laboratory services to its customers. www.diacarta.com

Contact:

Ram Vairavan PhD


Senior Vice President, DiaCarta Inc.


2600 Hilltop Drive


Richmond, CA 94906


[email protected]

 

SOURCE DiaCarta Inc.


These press releases may also interest you

at 08:35
Arch Insurance North America (Arch), a provider of specialized insurance and risk management solutions, today unveiled its latest products available through the Arch APEX? digital platform. Participant Accident coverage is now available for child...

at 08:35
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B...

at 08:35
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial...

at 08:30
Solitario Resources Corp. ("Solitario") is pleased to report that it has discovered another high-grade gold zone on its Golden Crest project, named Sleeping Beauty. Recently received assay results from reconnaissance rock sampling of...

at 08:30
Camber Energy, Inc. ("Camber" or the "Company"), today announced that on March 26, 2024, the U.S. Patent and Trademark Office (USPTO) issued U.S. patent11,942,776 entitled "Electric Transmission Line Ground Fault Prevention...

at 08:20
The "Highly Potent API Market - A Global and Regional Analysis: Focus on Type, Type of Synthesis, Therapeutic Area, Type of Manufacturing, End User, and Country - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's...



News published on and distributed by: